Epigenetix, Neomed Institute deal

Not-for-profit life sciences research center Neomed and Epigenetix partnered to develop bromodomain containing 4 (BRD4) inhibitors as an epigenetic modulator to treat cancer. The partners are aiming to select a drug candidate within six to eight months, and Neomed said the partners plan to develop candidates through human proof-of-concept. Neomed said it has inlicensed the program and will lead development in collaboration with Epigenetix, and that the parties will "share the benefits" from outlicensing. The partners declined to disclose financial details. ...